BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 32569675)

  • 1. Synergic effect of OP449 and FTY720 on oral squamous cell carcinoma.
    Goto RN; Sobral LM; Stringhetta-Padovani K; Garcia CB; da Silva G; Vitek MP; Leopoldino AM
    Eur J Pharmacol; 2020 Sep; 882():173268. PubMed ID: 32569675
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antagonism of SET using OP449 enhances the efficacy of tyrosine kinase inhibitors and overcomes drug resistance in myeloid leukemia.
    Agarwal A; MacKenzie RJ; Pippa R; Eide CA; Oddo J; Tyner JW; Sears R; Vitek MP; Odero MD; Christensen DJ; Druker BJ
    Clin Cancer Res; 2014 Apr; 20(8):2092-103. PubMed ID: 24436473
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PP2A deactivation is a common event in oral cancer and reactivation by FTY720 shows promising therapeutic potential.
    Velmurugan BK; Lee CH; Chiang SL; Hua CH; Chen MC; Lin SH; Yeh KT; Ko YC
    J Cell Physiol; 2018 Feb; 233(2):1300-1311. PubMed ID: 28516459
    [TBL] [Abstract][Full Text] [Related]  

  • 4. FTY720 increases paclitaxel efficacy in cisplatin-resistant oral squamous cell carcinoma.
    Torres LAT; Silva G; Alves JSF; Ushida TR; Potenza J; Garcia CB; Sousa LO; Lopes NP; Almeida LO; Leopoldino AM
    J Oral Pathol Med; 2024 Jan; 53(1):42-52. PubMed ID: 37946676
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sphingosine analogue drug FTY720 targets I2PP2A/SET and mediates lung tumour suppression via activation of PP2A-RIPK1-dependent necroptosis.
    Saddoughi SA; Gencer S; Peterson YK; Ward KE; Mukhopadhyay A; Oaks J; Bielawski J; Szulc ZM; Thomas RJ; Selvam SP; Senkal CE; Garrett-Mayer E; De Palma RM; Fedarovich D; Liu A; Habib AA; Stahelin RV; Perrotti D; Ogretmen B
    EMBO Mol Med; 2013 Jan; 5(1):105-21. PubMed ID: 23180565
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The NMR-based characterization of the FTY720-SET complex reveals an alternative mechanism for the attenuation of the inhibitory SET-PP2A interaction.
    De Palma RM; Parnham SR; Li Y; Oaks JJ; Peterson YK; Szulc ZM; Roth BM; Xing Y; Ogretmen B
    FASEB J; 2019 Jun; 33(6):7647-7666. PubMed ID: 30917007
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antagonistic activities of the immunomodulator and PP2A-activating drug FTY720 (Fingolimod, Gilenya) in Jak2-driven hematologic malignancies.
    Oaks JJ; Santhanam R; Walker CJ; Roof S; Harb JG; Ferenchak G; Eisfeld AK; Van Brocklyn JR; Briesewitz R; Saddoughi SA; Nagata K; Bittman R; Caligiuri MA; Abdel-Wahab O; Levine R; Arlinghaus RB; Quintas-Cardama A; Goldman JM; Apperley J; Reid A; Milojkovic D; Ziolo MT; Marcucci G; Ogretmen B; Neviani P; Perrotti D
    Blood; 2013 Sep; 122(11):1923-34. PubMed ID: 23926298
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A novel FTY720 analogue targets SET-PP2A interaction and inhibits growth of acute myeloid leukemia cells without inducing cardiac toxicity.
    Vicente C; Arriazu E; Martínez-Balsalobre E; Peris I; Marcotegui N; García-Ramírez P; Pippa R; Rabal O; Oyarzábal J; Guruceaga E; Prósper F; Mateos MC; Cayuela ML; Odero MD
    Cancer Lett; 2020 Jan; 468():1-13. PubMed ID: 31593801
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PP2A inhibition is a common event in colorectal cancer and its restoration using FTY720 shows promising therapeutic potential.
    Cristóbal I; Manso R; Rincón R; Caramés C; Senin C; Borrero A; Martínez-Useros J; Rodriguez M; Zazo S; Aguilera O; Madoz-Gúrpide J; Rojo F; García-Foncillas J
    Mol Cancer Ther; 2014 Apr; 13(4):938-47. PubMed ID: 24448818
    [TBL] [Abstract][Full Text] [Related]  

  • 10. FTY720 Induces Autophagy-Associated Apoptosis in Human Oral Squamous Carcinoma Cells, in Part, through a Reactive Oxygen Species/Mcl-1-Dependent Mechanism.
    Bai LY; Chiu CF; Chiu SJ; Chu PC; Weng JR
    Sci Rep; 2017 Jul; 7(1):5600. PubMed ID: 28717222
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aberrant expression of the S1P regulating enzymes, SPHK1 and SGPL1, contributes to a migratory phenotype in OSCC mediated through S1PR2.
    Patmanathan SN; Johnson SP; Lai SL; Panja Bernam S; Lopes V; Wei W; Ibrahim MH; Torta F; Narayanaswamy P; Wenk MR; Herr DR; Murray PG; Yap LF; Paterson IC
    Sci Rep; 2016 May; 6():25650. PubMed ID: 27160553
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro and in vivo synergistic anti-tumor effect of LIN28 inhibitor and metformin in oral squamous cell carcinoma.
    Chen H; Sa G; Li L; He S; Wu T
    Eur J Pharmacol; 2021 Jan; 891():173757. PubMed ID: 33249080
    [TBL] [Abstract][Full Text] [Related]  

  • 13. FTY720 inhibits mesothelioma growth in vitro and in a syngeneic mouse model.
    Szymiczek A; Pastorino S; Larson D; Tanji M; Pellegrini L; Xue J; Li S; Giorgi C; Pinton P; Takinishi Y; Pass HI; Furuya H; Gaudino G; Napolitano A; Carbone M; Yang H
    J Transl Med; 2017 Mar; 15(1):58. PubMed ID: 28298211
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The therapeutic effects of SET/I2PP2A inhibitors on canine melanoma.
    Enjoji S; Yabe R; Fujiwara N; Tsuji S; Vitek MP; Mizuno T; Nakagawa T; Usui T; Ohama T; Sato K
    J Vet Med Sci; 2015 Nov; 77(11):1451-6. PubMed ID: 26062569
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cell division cycle 7 is a potential therapeutic target in oral squamous cell carcinoma and is regulated by E2F1.
    Jin S; Ma H; Yang W; Ju H; Wang L; Zhang Z
    J Mol Med (Berl); 2018 Jun; 96(6):513-525. PubMed ID: 29713760
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Overexpression of PP2A inhibitor SET oncoprotein is associated with tumor progression and poor prognosis in human non-small cell lung cancer.
    Liu H; Gu Y; Wang H; Yin J; Zheng G; Zhang Z; Lu M; Wang C; He Z
    Oncotarget; 2015 Jun; 6(17):14913-25. PubMed ID: 25945834
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of Pten deficient Castration Resistant Prostate Cancer by Targeting of the SET - PP2A Signaling axis.
    Hu X; Garcia C; Fazli L; Gleave M; Vitek MP; Jansen M; Christensen D; Mulholland DJ
    Sci Rep; 2015 Nov; 5():15182. PubMed ID: 26563471
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chitosan nanocarrier for FTY720 enhanced delivery retards Parkinson's disease via PP2A-EzH2 signaling in vitro and ex vivo.
    Sardoiwala MN; Karmakar S; Choudhury SR
    Carbohydr Polym; 2021 Feb; 254():117435. PubMed ID: 33357908
    [TBL] [Abstract][Full Text] [Related]  

  • 19. LncRNA UCA1 promotes proliferation and cisplatin resistance of oral squamous cell carcinoma by sunppressing miR-184 expression.
    Fang Z; Zhao J; Xie W; Sun Q; Wang H; Qiao B
    Cancer Med; 2017 Dec; 6(12):2897-2908. PubMed ID: 29125238
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PP2A activation alone and in combination with cisplatin decreases cell growth and tumor formation in human HuH6 hepatoblastoma cells.
    Stafman LL; Williams AP; Marayati R; Aye JM; Stewart JE; Mroczek-Musulman E; Beierle EA
    PLoS One; 2019; 14(4):e0214469. PubMed ID: 30969990
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.